Drug intelligence / Profile preview

NNC0650-0013

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous, Intravenous

Overview

NNC0650-0013 is an investigational drug being developed by Novo Nordisk for the treatment of type 2 diabetes mellitus. It is currently in Phase I clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers following single ascending doses administered either subcutaneously or intravenously. As an early-stage compound, its specific molecular target and mechanism of action have not been publicly disclosed by the developer, though its development aligns with Novo Nordisk's focus on metabolic diseases and injectable therapies.

Targets

GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on NNC0650-0013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0650-0013.

Explore the full profile